Par Drugs And Chemicals growth ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+2.7%+5.6%−0.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−12.2%−14.5%+25.3%
−15.3%−18.2%+29.4%
−1.9%−7.9%+27.9%
−1.9%−7.8%+27.9%
+8.2%+17.5%+14.3%
+13.1%+15.6%+20.2%
+1.7%−20.2%+51.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-0.1+5.6+2.7—
EBITDA Growth—+25.3-14.5-12.2—
EBIT Growth—+29.4-18.2-15.3—
Net Income Growth—+27.9-7.9-1.9—
EPS Growth—+27.9-7.8-1.9—
Total Assets Growth—+14.3+17.5+8.2—
Total Equity Growth—+20.2+15.6+13.1—
Cash from Operations Growth—+51.4-20.2+1.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.